Daily Respiratory Research Analysis
Analyzed 47 papers and selected 3 impactful papers.
Summary
Analyzed 47 papers and selected 3 impactful articles.
Selected Articles
1. Nutritional anemia is associated with increased risk of severe COPD exacerbations: a prospective cohort study.
In 32,152 hospitalized AECOPD patients, anemia (18.5%), predominantly nutritional, was associated with higher post-discharge mortality (aHR 1.30) and readmission (aHR 1.08). Nutritional anemia specifically increased readmission risk (aHR 1.18), and subtype-tailored treatments (iron, B12, ESA) were associated with lower mortality within respective subgroups.
Impact: This large, prospective nationwide cohort identifies a common, modifiable comorbidity—nutritional anemia—as a driver of adverse outcomes after severe COPD exacerbations, with actionable, subtype-specific treatment signals.
Clinical Implications: Incorporate routine screening for iron deficiency and nutritional anemia during and after AECOPD hospitalization, and consider targeted correction (iron, B12, ESA as appropriate) within multidisciplinary COPD discharge pathways to reduce mortality and readmissions.
Key Findings
- Among 32,152 AECOPD patients, 18.5% had anemia; nutritional anemia constituted 49.3% and anemia of chronic disease 31.3%.
- Anemia was associated with higher post-discharge mortality (aHR 1.30, 95% CI 1.23–1.37) and higher AECOPD readmission risk (aHR 1.08, 95% CI 1.03–1.14).
- Nutritional anemia uniquely increased readmission risk (aHR 1.18, 95% CI 1.10–1.25); hematologic anemia showed the highest mortality risk (aHR 1.75).
- Subtype-tailored treatments (iron, vitamin B12, ESA) were associated with lower mortality in nutritional anemia; regimen–outcome associations differed by subtype.
Methodological Strengths
- Prospective nationwide cohort with large sample size (N=32,152).
- Multivariable Cox regression with adjustment for key confounders and IPTW analysis for treatment effects by anemia subtype.
Limitations
- Observational design susceptible to residual confounding and indication bias.
- Anemia treatment allocation was non-randomized; causal inference for therapies is limited.
Future Directions: Conduct randomized or pragmatic trials testing iron, B12, and ESA strategies in COPD with defined anemia phenotypes; integrate anemia management into COPD care bundles and evaluate impact on post-discharge outcomes.
BACKGROUND: Anemia prevalence in chronic obstructive pulmonary disease (COPD) varies widely across studies, and data on anemia subtypes and their association with mortality or COPD exacerbation readmission is limited. OBJECTIVE: We aimed to investigate anemia subtypes and their association with mortality and readmission for acute exacerbation of COPD (AECOPD) in patients hospitalized for AECOPD. METHODS: In this prospective observational cohort study, COPD patients ≥45 years hospitalized for severe exacerbations in a Belgian nationwide databa
2. Efficacy, safety, and tolerability of treatments for interstitial lung disease associated with rtoid arthritis: A systematic review and network meta-analysis.
Across 27 studies (n=8,186; 14 regimens), methotrexate, tocilizumab, and rituximab were associated with lower all-cause mortality; abatacept plus methotrexate reduced ILD progression; antifibrotics (nintedanib, pirfenidone) better preserved FVC or slowed decline; and JAK inhibitors showed the lowest discontinuation and highest retention.
Impact: This NMA synthesizes fragmented evidence to inform regimen selection in RA-ILD across critical outcomes (mortality, progression, lung function, tolerability), an area lacking head-to-head trials.
Clinical Implications: Consider methotrexate, tocilizumab, or rituximab when mortality reduction is prioritized; abatacept+MTX for progression risk; antifibrotics for FVC preservation; and JAK inhibitors in patients requiring high tolerability—pending confirmation in prospective controlled studies.
Key Findings
- Meta-analysis of 27 studies (2 RCTs, 25 observational; n=8,186) comparing 14 regimens in RA-ILD.
- Methotrexate, tocilizumab, and rituximab were associated with lower all-cause mortality.
- Abatacept plus methotrexate reduced ILD progression risk.
- Nintedanib and pirfenidone were associated with better preservation or slower decline of FVC%.
- JAK inhibitors had the lowest discontinuation (7.9%) and highest retention (81.7%).
Methodological Strengths
- Bayesian random-effects network meta-analysis integrating multiple outcomes.
- Risk of bias assessed with RoB 2 and Newcastle–Ottawa Scale across diverse designs.
Limitations
- Predominance of observational studies introduces confounding and treatment selection biases.
- Heterogeneity in patient characteristics, ILD patterns, and outcome definitions across studies.
Future Directions: Head-to-head pragmatic RCTs in RA-ILD with harmonized outcomes and imaging; biomarker- or phenotype-guided treatment algorithms; prospective evaluation of combined immunomodulatory and antifibrotic strategies.
OBJECTIVES: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a severe and potentially life-threatening pulmonary complication. Therapeutic approaches are heterogeneous, and high-quality head-to-head comparative evidence remains scarce. This network meta-analysis (NMA) aimed to compare the efficacy, safety, and tolerability of pharmacological regimens used in RA-ILD. METHODS: We systematically searched PubMed, Embase, Cochrane Library, Scopus, and ClinicalTrials.gov up to 8 July 2025, enrolling adult pa
3. Plasma proteomics reveal SERPINA1 and CD59 as candidate biomarkers for COVID-19 severity stratification and prognosis prediction.
Unbiased plasma proteomics across COVID-19 severity identified SERPINA1 and CD59 as independent prognostic biomarkers. SERPINA1 predicted 30-day and 12-month mortality (AUC 0.775 and 0.924), CD59 predicted sepsis (AUC 0.720), and the combined model markedly improved prediction of 12-month mortality (AUC 0.946) and sepsis (AUC 0.904), outperforming D-dimer and FDP.
Impact: The study advances prognostic stratification in COVID-19 by nominating proteomic biomarkers that outperform widely used hemostasis markers and underscore the role of coagulation/complement pathways.
Clinical Implications: Pending prospective validation, SERPINA1 and CD59 could support early risk stratification for mortality and sepsis and inform monitoring or prophylaxis for thromboinflammation in severe COVID-19.
Key Findings
- Severity-associated enrichment of coagulation and complement pathways was observed across proteomic profiles.
- SERPINA1 predicted 30-day and 12-month mortality (AUC 0.775 and 0.924).
- CD59 predicted sepsis (AUC 0.720); the combined model improved prediction of 12-month mortality (AUC 0.946) and sepsis (AUC 0.904).
- The biomarker model outperformed D-dimer and FDP, and multivariable regression confirmed independent prognostic value.
Methodological Strengths
- Unbiased plasma proteomics with differential expression, clustering, and pathway analyses across severity classes.
- Independent cohort validation, bootstrap-corrected ROC analyses, and multivariable regression confirming independence.
Limitations
- Exploratory observational design; potential cohort heterogeneity and overfitting despite bootstrap correction.
- Clinical utility and generalizability require prospective, multicenter validation and impact analyses.
Future Directions: Prospective multicenter validation with predefined thresholds, integration with clinical scores, and mechanistic studies probing SERPINA1/complement biology to guide targeted interventions.
BACKGROUND: COVID-19 has been closely associated with coagulation abnormalities. However, existing biomarkers, including D-dimer and fibrin degradation products (FDP), exhibit limited accuracy in stratifying disease severity and predicting long-term clinical outcomes. OBJECTIVES: This study aimed to use proteomic analysis to identify plasma biomarkers associated with COVID-19 severity and prognosis, and validate their predictive utility for mortality and thromboembolic complications. METHODS: Plasma proteomic profiles were an